Spring 2018 Teasers
Drug Discovery World
Bringing IO together: how an immunologist and oncologist collaborate
By Dr Julia Schuler and Dr Louise Brackenbury

For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing novel treatments for patients.

From checkpoint inhibitors to CAR-T cells and model selection designed to reflect more personalised medicine approaches, immuno-oncology is shifting how both immunologists and oncologists approach drug discovery and development.

In a Q&A, Dr Julia Schüler, DVM, Research Director at Charles River, which specialises in oncology, and Dr Louise Brackenbury, Principal Scientist for Cell Biology at Charles River’s newlyacquired KWS BioTest, which specialises in immunology, will provide their unique perspectives on the ways in which IO is reshaping the industry...

You just need to REGISTER - its FREE - to read the rest of this article straight away.